Skip to main content
Rezolute, Inc. logo

Rezolute, Inc. — Investor Relations & Filings

Ticker · RZLT ISIN · US76200L3096 LEI · 549300T05L48T72P2G08 US Manufacturing
Filings indexed 720 across all filing types
Latest filing 2026-03-26 Major Shareholding Noti…
Country US United States of America
Listing US RZLT

About Rezolute, Inc.

https://www.rezolutebio.com/

Rezolute, Inc. is a late-stage biopharmaceutical company dedicated to developing therapies for rare diseases. The company's primary focus is on addressing hypoglycemia caused by hyperinsulinism (HI). Its lead product candidate, ersodetug, is being developed as a potential treatment for hypoglycemia related to both congenital and tumor-induced hyperinsulinism. Rezolute is advancing ersodetug through two ongoing Phase 3 clinical trials for these indications, aiming to provide a novel therapeutic option for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G/A - Rezolute, Inc. (0001509261) (Subject)
Major Shareholding Notification
2026-03-26 English
8-K - Rezolute, Inc. (0001509261) (Filer)
Regulatory Filings
2026-03-24 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-13 English
8-K - REZOLUTE, INC. (0001509261) (Filer)
Regulatory Filings
2026-02-12 English
10-Q Filing
Interim / Quarterly Report Q2 2026
2026-02-12 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-01-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.